Oct 2026· British Journal of Cancer· 0 citations· 66 references
Medicine
TL;DR
This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
Abstract
Background
In colorectal cancer (CRC), tumor-immune interactions are critical drivers of tumorigenesis, immune evasion, and therapeutic response. Therefore, a deeper spatially resolved understanding of these interactions is urgently needed.
Methods
Spatial transcriptomics (ST) of CRC and matched normal samples was used to characterize cell populations and gene expression patterns associated with tumorigenesis and immune infiltration. An additional 41 publicly available ST slides, single-cell transcriptomics and bulk transcriptomics datasets from 472 and 617 CRC patients, respectively, were analyzed to validate the findings.
Results
Cancer regions exhibited profound molecular alterations with increased oncogenic pathways, immunosuppressors, and tryptophan deprivation via KYNU-AHR axis, inducing the macrophage attractant CXCL5, contributing to immune evasion. In tumor boundaries, SPP1⁺ macrophages fostered an immunosuppressive microenvironment with regulatory T-cells (Tregs) recruited via CCL18-CCR8 and CCL22-CCR4. SIT1 emerged as a potential anti-tumor T-cells suppressor within tertiary lymphoid structures, suggesting a novel immune regulator. We also uncovered a previously uncharacterized population of tumor-infiltrating IFI6⁺ Tregs associated with unfavorable prognosis and therapy response, defined by elevated interferon-related genes and LGALS9, a potential immune checkpoint target.
Conclusion
This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.
CRLM is associated with altered NK-cell representation among recovered cells and a reproducible CCL4-enriched inflammatory NK-cell transcriptional state and its association with inflammatory and myeloid-stromal programs across independent, spatial and model-system analyses provides a focused framework for future lineag...
Li-Hong Lin, Michael Xu, Xiao-Chun Gu et al.· Frontiers in Immunology· 0 citations
Single-cell transcriptomics of publicly available BLCA data identifies two transcriptionally distinct fibroblast states in adjacent tissue and supports an exploratory ligand–receptor interaction framework, warranting prospective validation with primary CAF populations and adequately powered multi-specimen cohorts.
Yan-Dong He, Wen-Long Lu, Guan-Qun Ju et al.· Frontiers in Cell and Develo...· 0 citations
BACKGROUND
Colorectal cancer (CRC) is characterized by marked epithelial heterogeneity and dynamic tumor-microenvironment interactions. However, epithelial states associated with progression across the normal-adenoma-carcinoma sequence remain incompletely defined.
METHODS
Single-cell RNA sequencing data from normal c...
Genetic and transcriptional alterations in cancer cells shape their interactions with immune and stromal compartments, thereby influencing tumor progression, immune evasion, and response to immune checkpoint inhibitors (ICIs). Yet, how these interactions are spatially organized within melanoma and how they relate to cl...
Milad Ibrahim, Irineu Illa-Bochaca, T. Muijlwijk et al.· Molecular Cancer· 0 citations
ZDHHC12 may serve as a candidate pan-cancer prognostic biomarker and its expression was broadly correlated with immune cell recruitment- and activation-related signatures in glioma and in glioma, and was associated with patient prognosis.
Chao Zhang, Da Teng, Yu Wang et al.· Journal of Cancer· 0 citations
The findings suggest an ECM–CD44 axis linking tumor mesenchymal programs to M2-like polarization and increased macrophage infiltration in stromal and sarcomatoid areas compared to clear cell regions.
Katsuhiro Ito, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.